Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05420961 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 717
- Enrollment target
NCT05420961 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 717 participants.
The verdict
NCT05420961, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 717 participants
- Enrollment target
Study Summary
This a study of V116 in adults ≥50 years of age who previously received a pneumococcal vaccination ≥1 year before enrollment. The primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of V116.
Interventions
- BIOLOGICAL V116
- BIOLOGICAL PPSV23
- BIOLOGICAL PCV15
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 717 participants |
| Start Date | 2022-07-12 |
| Est. Completion | 2023-05-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05420961
The ClinicalTrials.gov registry entry for NCT05420961 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 717 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which V116 is the first listed.
NCT05420961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05420961 about?
NCT05420961 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)". This a study of V116 in adults ≥50 years of age who previously received a pneumococcal vaccination ≥1 year before enrollment. The primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of V116.
What is the current status of trial NCT05420961?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 717 participants. The study started on 2022-07-12. Estimated completion is 2023-05-16.
What interventions are being tested in trial NCT05420961?
The interventions under investigation include: V116 (BIOLOGICAL), PPSV23 (BIOLOGICAL), PCV15 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05420961?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.